BioSpace News Archive

Policy

Novoclem Therapeutics Receives QIDP Status for its Lead Inhaled Antimicrobial Drug Candidate

The QIDP designation, granted for treatment of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis, will make BIOC51 eligible to benefit from certain incentives for the development of new antibiotics provided under the Generating Antibiotic Incentives Now Act.

November 7, 2017

·

3 min read

Business

Zynex Schedules 2017 Third Quarter Earnings Release and Webcast

The Company expects to file its 2017 third quarter financial results on Monday, November 13, 2017.

November 7, 2017

·

2 min read

Business

Agenus Reports Third Quarter 2017 Financial Results and Provides Corporate Update

Agenus provided a corporate update and reported financial results for the third quarter ended September 30, 2017.

November 7, 2017

·

11 min read

Biotech Bay

Fitbit Selected for NIH Precision Medicine Research Program With The Scripps Research Institute

Researchers will use data gathered from the program to learn more about how individual differences in lifestyle, environment and biological makeup can influence health and disease.

November 7, 2017

·

4 min read

Biotech Bay

Jaguar Health Receives Approval From The American Association of Veterinary State Boards RACE Committee for Continuing Education Program for Veterinarians and Veterinary Technicians on Diarrhea in Foals

Jaguar Health announced today that The American Association of Veterinary State Boards (AAVSB) Registry of Approved Continuing Education (RACE) committee has reviewed and approved Jaguar’s “Diarrhea in Foals” continuing education (CE) program as meeting the standards adopted by the AAVSB.

November 7, 2017

·

4 min read

GeoVax Publishes Zika Vaccine Study Results in Nature’s Scientific Reports

The paper published today reports research showing that a single intramuscular dose of GeoVax’s Zika vaccine (GEO-ZM02) provided 100% protection in normal mice challenged with a lethal dose of Zika virus (ZIKV) delivered directly into the brain.

November 7, 2017

·

5 min read

Drug Development

OncoQuest Announces Presentation of Translational Immunology Data from Phase II Clinical Study Examining Oregovomab

The findings presented were drawn from the 81 patients in the trial from the Italian investigative centers.

November 7, 2017

·

3 min read

Policy

Batu Biologics Receives FDA Clearance for First Multi-Pronged Immunotherapy Targeting the Blood Vessels That Feed Cancer

Batu Biologics, an immuno-oncology company dedicated to the development of its tumor-angiogenesis targeting immune therapy, ValloVax™, has received an Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) allowing Batu to proceed with Phase 1 clinical trials.

November 7, 2017

·

3 min read

Deals

Ultragenyx Completes Tender Offer and Acquisition of Dimension Therapeutics

Ultragenyx purchased all outstanding shares of common stock of Dimension for $6.00 per share in cash, without interest, or approximately $152.3 million in cash.

November 7, 2017

·

4 min read

Policy

Collegium Receives FDA Approval for sNDA for Xtampza ER

With approval of the sNDA, the updated label for Xtampza ER includes three main changes.

November 7, 2017

·

10 min read